Shanghai Shyndec Pharmaceutical Co., Ltd.

SHSE:600420 Stock Report

Market Cap: CN¥16.2b

Shanghai Shyndec Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Yong Liu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.1yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Dec 12
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Nov 17
Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Oct 08
Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Aug 23
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

May 06
Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

Apr 30
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Apr 05
Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

CEO

Yong Liu (55 yo)

less than a year

Tenure

Mr. Yong Liu is Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 and serves as President Since September 2024.

Leadership Team

NamePositionTenureCompensationOwnership
Yong Liu
Vice Chairman of the Board & Presidentless than a yearno datano data
Xian Lin Li
VP & General Counsel2.7yrsCN¥1.43m0.0015%
CN¥ 241.4k
Dongsong Wei
VP & Secretary of the Board of Directors13.3yrsCN¥1.46m0.0015%
CN¥ 241.4k
Feng Ni
Vice President2.1yrsCN¥914.60k0.0015%
CN¥ 241.4k
Jing Zu
Chief Financial Officerless than a yearCN¥344.90kno data

2.1yrs

Average Tenure

54yo

Average Age

Experienced Management: 600420's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yong Liu
Vice Chairman of the Board & President3.7yrsno datano data
Yingqi Li
Independent Director2.1yrsCN¥240.00kno data
Peng Wang
Director2.1yrsno datano data
Ru Li
Director2.1yrsno datano data
Zenghe Dong
Chairman5.8yrsno datano data
Xiangdong Yu
Supervisor5.9yrsno data0.0015%
CN¥ 241.4k
Kan Tian
Independent Director5.8yrsCN¥240.00kno data
Yonggang Xing
Chairman of the Supervisory Board5.1yrsno datano data
Shuyuan Wei
Director4.6yrsno datano data
Fanhong Wu
Independent Director3.7yrsCN¥240.00kno data
Yonghua Zuo
Supervisor2.1yrsno datano data

3.7yrs

Average Tenure

55yo

Average Age

Experienced Board: 600420's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 17:15
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Shyndec Pharmaceutical Co., Ltd. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
null RESEARCH DEPARTMENTChina Merchants Securities Co. Ltd.
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)